[go: up one dir, main page]

WO2018056600A1 - Composition topique pour apaiser la peau, contenant comme principe actif un extrait de germe de blé fermenté - Google Patents

Composition topique pour apaiser la peau, contenant comme principe actif un extrait de germe de blé fermenté Download PDF

Info

Publication number
WO2018056600A1
WO2018056600A1 PCT/KR2017/009499 KR2017009499W WO2018056600A1 WO 2018056600 A1 WO2018056600 A1 WO 2018056600A1 KR 2017009499 W KR2017009499 W KR 2017009499W WO 2018056600 A1 WO2018056600 A1 WO 2018056600A1
Authority
WO
WIPO (PCT)
Prior art keywords
wheat germ
skin
formula
extract
present application
Prior art date
Application number
PCT/KR2017/009499
Other languages
English (en)
Korean (ko)
Inventor
양태주
오한나
이지훈
박승원
이상범
조성준
Original Assignee
씨제이제일제당 (주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨제이제일제당 (주) filed Critical 씨제이제일제당 (주)
Publication of WO2018056600A1 publication Critical patent/WO2018056600A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present application relates to an external preparation composition having excellent skin sedative effect, and specifically, 2,6-dimethoxybenzoquinone, or a wheat germ fermentation product or extract thereof, and a composition for skin soothing, preventing or treating inflammatory skin diseases. And to a quasi-drug composition for skin soothing.
  • the conventional anti-inflammatory agent is in most cases can not be used as a cosmetic raw material or the amount of use is limited.
  • steroidal anti-inflammatory drugs are accompanied by side effects such as skin atrophy, insomnia and anxiety. Therefore, the development of natural raw materials which are excellent for skin safety and effective for soothing the skin are actively made (see Korean Patent Publication Nos. 10-2011-0038546, 10-2010-0086698 and 10-2012-0015881). ).
  • the present inventors have made intensive studies to develop a skin sedative cosmetic composition comprising a natural substance, and as a result, the composition comprising 2,6-dimethoxybenzoquinone, or wheat germ fermentation product or extract thereof has a cytotoxic effect.
  • the present application was confirmed by showing a soothing effect without showing the skin.
  • An object of the present application is to provide a skin calming cosmetic composition comprising a compound of Formula 1, or wheat germ fermentation or extracts thereof.
  • Another object of the present application is to provide a pharmaceutical composition for preventing or treating inflammatory skin diseases comprising the compound of Formula 1, or wheat germ fermentation or extracts thereof.
  • Another object of the present application to provide a method for preventing, ameliorating or treating inflammatory skin disease comprising administering to a subject in need thereof a composition comprising the compound of Formula 1, or wheat germ fermentation product or extract thereof. will be.
  • Another object of the present application to provide a quasi-drug quaternary composition comprising the compound of Formula 1, or wheat germ fermentation or extract thereof.
  • Another object of the present application is to provide a method for calming the skin, comprising the step of administering to a subject in need thereof a composition comprising the compound of formula 1 or wheat germ fermentation or extract thereof.
  • the present application provides a skin calming cosmetic composition comprising a compound of Formula 1, or wheat germ fermentation or extract thereof.
  • Compound which may be included as an active ingredient in the cosmetic composition of the present application may be a compound represented by the following formula (1).
  • the compound of Formula 1 refers to 2,6-dimethoxycyclohexa-2,5-diene-1,4-dione (2,6-Dimethoxycyclohexa-2,5-diene-1,4-dione) In the application it may be mixed with 2,6-DMBQ, 2,6-dimethoxybenzoquinone or dimethoxybenzoquinone. Specifically, the compound of Formula 1 may be in a nonglycoside form.
  • the compound of Chemical Formula 1 may be synthesized chemically or biologically, or may be purchased and used commercially. Alternatively, it can be obtained by separating from natural products (eg, plants, etc.) known to contain the compounds of the present application. However, it is not particularly limited thereto.
  • the compound of Formula 1 may include both physiologically acceptable salts of the compound of Formula 1 as well as possible solvates and hydrates that may be prepared therefrom.
  • the compound of Formula 1 may exhibit an anti-inflammatory effect and may have a skin soothing effect.
  • Wheat germs of the present application may include, but are not limited to, dried embryos, milled products, concentrates and mixtures thereof.
  • the term “fermentation” refers to any activity or process, including enzymatic or metabolic degradation of organic materials using microorganisms.
  • the term “wheat embryo fermentation” refers to the result of enzymatic or metabolic degradation of wheat germ using microorganisms.
  • Wheat germ fermentation of the present application may include a compound of formula (1) of the present application.
  • wheat germ fermentation of the present application may be obtained by inoculating microorganisms in wheat germ or a medium containing the same and then cultured.
  • the microorganism may be at least one selected from the group consisting of yeast, lactic acid bacteria, bacteria, and fungi.
  • yeast Saccharomyces Roman Isis celebrity kids Vichy Saccharomyces cerevisiae
  • Saccharomyces access to my ellipsis Soi Deus S. ellipsoideus
  • Saccharomyces access to my Correa Augustine S. coreanus
  • Saccharomyces access to My Carlsbad beojen system S. carlsbergensis
  • S. pastorianus S. lactis
  • S. rouxii S. rouxii
  • Schizosaccharomyces pombe Schizosaccharomyces major
  • Hansenula anomala Hansenula anomala
  • Brettanomyces bruxellensis B.
  • the yeast may be Saccharomyces cerevisiae.
  • the lactic acid bacteria are for example Bifidobacterium sp . ), Lactobacillus sp . , Lactococcus sp . ), Peddie Oh caucus in (Pediococcus sp.), May be a microorganism Streptococcus genus (Streptococcus. Sp), or the current Kono Stock in (Leuconostoc sp.), Filed a wheat germ fermented or its extract of the present application It is not limited to this as long as it can have a soothing effect on the skin.
  • the lactic acid bacteria are Bifidobacterium bifidum ( B.
  • Bifidum Bifidobacterium breve
  • B. longum Bifidobacterium animalis
  • B. lactis Bifidobacterium lactis
  • Lactobacillus ashdophyllus L. acidophilus
  • Lactobacillus casei L. casei
  • Lactobacillus gaseri L. gasseri
  • Lactobacillus del brew Eki species L. delbrueckii spp .
  • Lactobacillus Bulgaria kusu L. bulgaricus
  • Lactobacillus helveticus L.
  • lactic acid bacteria may be used in the same sense as lactic acid bacteria.
  • the fungus used in the fermentation may include, but is not limited to, mushrooms, for example, shiitake mushrooms, oyster mushrooms, enoki mushrooms, matsutake mushrooms, mushroom mushrooms, tree mushrooms, roe deer mushrooms, It may be a ganoderma lucidum mushroom, or a situation mushroom, but is not limited thereto, as long as the wheat germ fermentation product of the present application or extract thereof may exhibit a skin soothing effect for the purpose of the present application.
  • the inoculation amount, the culture temperature, the culture humidity, and the incubation time of the microorganisms used to prepare the wheat germ fermentation product of the present application may be appropriately selected by those skilled in the art in consideration of the types of microorganisms used for the fermentation.
  • the culture of the present application may be carried out for 12 to 60 hours at a temperature of 20 °C to 40 °C.
  • the culture of the present application is 25 °C to 35 °C, 28 °C to 32 °C or 30 °C temperature and / or 12 hours to 50 hours, 20 hours to 50 hours, 30 hours to 50 hours, 35 hours to 45 hours, It may be carried out for 38 to 42 hours or 40 hours.
  • extract of wheat germ fermentation refers to a material that removes microorganisms from wheat germ fermentation.
  • Removal of the present application may include any method as long as it is a method for removing microorganisms (eg, yeast cells) contained in microorganism fermentation known in the art.
  • the extract of wheat germ fermentation of the present application may be a supernatant obtained by centrifuging the wheat germ fermentation of the present application. More specifically, the centrifugation is revolution per minute of 6,000 rpm to 10,000 rpm, 7000 rpm to 9000 rpm, 7500 rpm to 8500 rpm, 7800 rpm to 8200 rpm or 8000 rpm and / or 5 minutes to 120 minutes.
  • the extract of the wheat germ fermentation of the present application may include a compound of formula (1) of the present application.
  • Extracts of wheat germ fermentation of the present application include the extract of the wheat germ fermentation of the present application itself and extracts of all formulations that can be formed using extracts such as dilutions, concentrates, dry matters, crudes, tablets or mixtures thereof.
  • the extract of the wheat germ fermentation of the present application may be a dry matter, more specifically, it may be a freeze-dried product.
  • the extract of the wheat germ fermentation of the present application can be obtained from the wheat germ fermentation by any method as long as it has a skin soothing effect or a prevention, improvement or treatment effect of inflammatory skin disease
  • non-limiting example wheat germ fermentation Water immersion in a solvent, cold extraction method to extract at room temperature of 10 °C to 25 °C, heating extraction method to be extracted by heating to 40 °C to 100 °C, ultrasonic extraction method by applying ultrasonic waves, reflux extraction method using a reflux cooler and the like Can be used. These methods may be performed alone or in combination of two or more methods.
  • the kind of extraction solvent used for extraction of the present application is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the extraction solvent of the present application is a group consisting of water, alcohol having 1 to 4 carbon atoms, hexane, ethyl acetate, chloroform, dichloromethane and mixed solvents thereof
  • the solvent selected from, and specifically, the extraction solvent of the present application may be hot water.
  • the extract of the present application may be one containing a fraction thereof.
  • fraction refers to the result obtained by performing fractionation to separate a particular component or group of components from a mixture comprising several different components.
  • the fractionation method for obtaining a fraction of the present application is not particularly limited and may be performed according to a method conventionally used in the art. Solvent fractionation by treatment of various solvents, ultrafiltration fractionation through passage of ultrafiltration membranes with constant molecular weight cut-off values, and various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) Chromatography), and combinations thereof.
  • the type of fractional solvent used to obtain the fractions of the present application is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of fractional solvents of the present application include water, polar solvents such as alcohols having 1 to 6 carbon atoms; And nonpolar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of one or more.
  • Wheat germ fermentation product or extract thereof of the present application may be used in 0.001% to 10% by weight relative to the total weight of the composition of the present application, specifically 0.01% to 7% by weight, 0.01% to 5% by weight, 0.01 wt% to 3 wt%, 0.01 wt% to 2 wt%, 0.01 wt% to 1 wt%, 0.05 wt% to 10 wt%, 0.05 wt% to 7 wt%, 0.05 wt% to 5 wt%, 0.05 wt% % To 3%, 0.05% to 2%, 0.05% to 1%, 0.1% to 10%, 0.1% to 7%, 0.1% to 5%, 0.1% to 3 wt%, 0.1 wt% to 2 wt%, 0.1 wt% to 1 wt%, 0.5 wt% to 10 wt%, 0.5 wt% to 7 wt%, 0.5 wt% to 5 wt%, 0.5 wt
  • Wheat germ fermentation or extracts thereof of the present application may be included in the composition of the present application 0.1 ⁇ g / ml to 400 ⁇ g / ml.
  • the wheat germ fermentation product of the present application or extract thereof may be contained in the composition of the present application in the range of 25 ⁇ g / ml to 400 ⁇ g / ml, 50 ⁇ g / ml to 400 ⁇ g / ml, 100 ⁇ g / ml to 400 ⁇ g / ml or 200 ⁇ g. / ml to 400 ⁇ g / ml.
  • the compound represented by Formula 1 of the present application may be used in 0.00001% to 0.1% by weight relative to the total weight of the composition, specifically 0.00001% to 0.01% by weight, 0.00001% to 0.001% by weight, 0.00005% by weight % To 0.01 wt%, 0.00005 wt% to 0.001 wt%, 0.00005 wt% to 0.001 wt%, 0.0001 wt% to 0.01 wt%, 0.0001 wt% to 0.001 wt%, 0.0001 wt% to 0.001 wt%, 0.0005 wt% to 0.01 wt%, 0.0005 wt% to 0.001 wt%, 0.0005 wt% to 0.001 wt%, 0.0005 wt% to 0.001 wt%, or 0.0007 wt%.
  • the compound represented by Formula 1 of the present application may be included in the composition of the present application 15 ⁇ g / ml to 120 ⁇ g / ml.
  • the wheat germ fermentation product or extract thereof of the present application specifically contains the wheat germ fermentation product or extract thereof of the present application of 30 ⁇ g / ml to 120 ⁇ g / ml or 60 ⁇ g / ml in the composition of the present application To 120 ⁇ g / ml.
  • skin soothing in the present application means to relieve and subside the erythema or irritated skin areas and the like.
  • the skin soothing may include, but is not particularly limited to, inflammation improvement or treatment, reduction of transdermal moisture loss, and / or redness reduction as compared with the case where the composition according to the present invention is not treated.
  • the cause of skin soothing is not limited.
  • the skin inflammation may be improved by the composition of the present application so that the skin may be soothed.
  • Cosmetic compositions of the present application are in the group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, sprays and packs It may be formulated and provided in the form of choice.
  • the cosmetic composition of the present application may further include a cosmetically acceptable carrier.
  • the kind of cosmetically acceptable carrier of the present application is not particularly limited as long as it does not impair the activity and properties of the cosmetic composition of the present application, and any carriers commonly used in the art and cosmetically acceptable may be used.
  • Non-limiting examples of the cosmetically acceptable carrier include saline, sterile water, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more thereof.
  • the cosmetically acceptable carrier of the present application may include a non-naturally occuring carrier.
  • the cosmetically acceptable carrier of the present application varies depending on the formulation of the cosmetic composition.
  • the formulation of the cosmetic composition of the present application is a paste, cream or gel
  • animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide Etc. may be used, but is not limited thereto.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. may be used as a carrier component, and in particular, in the case of a spray, additionally chloro Propellants such as fluorohydrocarbons, propane / butane or dimethyl ether may be included, but are not limited thereto.
  • a solvent, a solubilizer or an emulsifier may be used as the carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl Benzoate, propylene glycol, 1,3-butylglycol oil and the like can be used, and in particular, cottonseed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or sorbitan Fatty acid ester of may be used, but is not limited thereto.
  • suspensions such as liquid diluents such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters as carrier components
  • liquid diluents such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters
  • microcrystalline cellulose, aluminum metahydroxyde, bentonite, agar or tracant may be used, but is not limited thereto.
  • the formulation of the cosmetic composition of the present application is a soap
  • a carrier component alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars and the like May be used, but is not limited thereto.
  • the formulation of the cosmetic composition of the present application is a pack, a wash off containing a pigment such as kaolin, talc, zinc oxide, or titanium dioxide in the peel-off pack containing polyvinyl alcohol or the like, or a general emulsion cosmetic It includes all forms of packs or mask sheet packs, but is not particularly limited thereto.
  • the cosmetic composition of the present application may further include components included in conventional skin external preparation components such as water, a surfactant, a moisturizer, a lower alcohol having 1 to 6 carbon atoms, a chelating agent, a bactericide, an antioxidant, a preservative, a pigment, and a perfume.
  • a surfactant such as water, a surfactant, a moisturizer, a lower alcohol having 1 to 6 carbon atoms, a chelating agent, a bactericide, an antioxidant, a preservative, a pigment, and a perfume.
  • the present application provides a pharmaceutical composition for preventing or treating inflammatory skin disease, comprising the compound of Formula 1, or wheat germ fermentation or extract thereof.
  • inflammatory skin disease refers to a skin disease whose main lesion is inflammation, which is seborrheic dermatitis, contact dermatitis, systemic lupus erythematosus, acne, eczema, acne, urticaria, psoriasis, It may be selected from the group consisting of lupus erythematosus, chronic simple mammary gland, interrogation, deprivation dermatitis and sun dermatitis, but is not limited thereto.
  • Extract of the compound of Formula 1, wheat germ, wheat germ fermentation and wheat germ fermentation is as described above.
  • prevention in the present application refers to any action that inhibits or delays the development of inflammatory skin disease by administration of a composition according to the present invention.
  • treatment refers to any activity in which the symptoms of inflammatory skin disease improve or benefit from administration of a pharmaceutical composition comprising a compound of formula 1, wheat germ fermentation, or extract of wheat germ fermentation of the present application. do.
  • the pharmaceutical composition may further include a pharmaceutically acceptable carrier.
  • the term "pharmaceutically acceptable carrier” refers to a carrier or diluent that does not stimulate an organism and does not inhibit the inflammatory skin disease preventive or therapeutic activity and properties of the pharmaceutical composition of the present application.
  • Acceptable pharmaceutical carriers in compositions formulated as liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol And one or more of these components may be used in combination, and other conventional additives such as antioxidants, buffers, bacteriostatic agents may be added as necessary.
  • the pharmaceutically acceptable carrier of the present application may include a non-naturally occuring carrier.
  • composition of the present application may be administered in a single or multiple doses in a pharmaceutically effective amount.
  • the term “pharmaceutically effective amount” means an amount sufficient to prevent or treat a disease at a reasonable benefit / risk ratio applicable to medical prophylaxis or treatment, and an effective dose level refers to the severity of the disease, Activity, body weight, health, sex of the patient, sensitivity to the drug of the patient, time of administration of the composition of the present application used, route of administration and rate of release, duration of treatment, drugs used in combination with or concurrently with the composition of the present application used Factors, and factors well known in the medical arts.
  • the present application provides a method for preventing or treating inflammatory skin disease, comprising administering to a subject in need thereof a composition comprising a compound of formula 1, or wheat germ fermentation or extract thereof. .
  • the compound of Formula 1, wheat germ fermented product, extract of wheat germ fermented product, inflammatory skin disease, prevention and treatment are as described above.
  • the suspicious subject of inflammatory skin disease in the present application means all animals including humans having or may develop inflammatory skin disease, and by administering the pharmaceutical composition of the present application to a subject suspected of inflammatory skin disease, Can be treated efficiently.
  • the term "administration" refers to the introduction of the pharmaceutical composition of the present invention to an individual suspected of having an inflammatory skin disease by any suitable method, and refers to any general route by which the composition of the present application can reach a target in vivo. It can be administered through.
  • the route of administration of the composition of the present application is not particularly limited, but can be administered orally or parenterally. Specifically, it may be administered parenterally, and more specifically, it may be applied in a manner of applying to the skin (ie, transdermal administration). Specifically, the administration of the present application may be carried out once to four times, two to three times or twice a day. In addition, administration of the present application may be carried out for a period of at least 4 weeks, at least 8 weeks, 4 to 12 weeks or 8 to 12 weeks.
  • the present application provides a quasi-drug quasi-drug composition comprising the compound of Formula 1, or wheat germ fermentation or extract thereof.
  • the compound of Formula 1, wheat germ fermented product, extract of wheat germ fermented product, and skin soothing are as described above.
  • quasi drug refers to articles that are less effective than drugs among those used for the purpose of diagnosing, treating, ameliorating, reducing, treating or preventing a disease of a human or animal. According to the article, quasi-drugs exclude products used for the purpose of medicines, and include products used for the treatment or prevention of diseases of humans and animals, and products with slight or no direct action on the human body.
  • the quasi-drug composition of the present application may be prepared in a form selected from the group consisting of body cleanser, foam, soap, mask, ointment, cream, lotion, essence and spray, but is not limited thereto.
  • the extract of the compound of formula (1), wheat germ fermentation or wheat germ fermentation of the present application is added as it is or with other quasi-drug or quasi-drug components It can use together and can use suitably according to a conventional method.
  • the mixing amount of the active ingredient may be appropriately determined depending on the intended use.
  • the present application provides a method of calming the skin, comprising administering to a subject in need thereof a composition comprising a compound of formula 1, or wheat germ fermentation or extract thereof.
  • the compound of Formula 1, wheat germ fermented product, extract of wheat germ fermented product, and skin soothing are as described above.
  • compositions comprising 2,6-DMBQ, or wheat germ fermentation, or extracts thereof, have no cytotoxicity and are safe, have good anti-inflammatory effects, as well as reduce percutaneous moisture loss and redness of the skin, soothing or inflammatory skin It can be used for disease prevention or treatment.
  • Figure 1 shows the cytotoxicity test results according to wheat germ fermentation concentration.
  • Figure 2 shows the NO production inhibitory ability according to the concentration of wheat germ fermentation.
  • Figure 3 shows the results of cell viability evaluation according to the concentration of 2,6-DMBQ.
  • Figure 4 shows the NO production inhibitory ability according to the concentration of 2,6-DMBQ.
  • FIG. 5 shows the transdermal moisture loss (TEWL) change according to Experimental Example 4.
  • FIG. 6 shows a change in skin redness (a-value) according to Experimental Example 4.
  • % used to denote the concentration of a particular substance is (weight / weight)% solids / solid and (weight / volume)% unless otherwise indicated. And liquid / liquid is (volume / volume)%.
  • wheat germ 50 g of wheat germ (CJ CheilJedang) and 500 g of water were added to the flask, mixed well, and sterilized at 121 ° C. for 15 minutes and cooled. Then, 5% (2.5 g) of dry yeast [bread yeast (Saccharomyces cerevisiae), Angel Yeast] was inoculated, fermented at 30 ° C. for 40 hours, and then 20 minutes at 8000 rpm. The supernatant was taken by centrifugation. The supernatant was lyophilized and recovered to prepare an extract of wheat germ fermentation.
  • dry yeast bread yeast (Saccharomyces cerevisiae), Angel Yeast
  • the extract of the wheat germ fermentation was named 'CJ'.
  • 2,6-DMBQ in the following experimental example was purchased from Sigma-Aldrich and used.
  • RAW 264.7 cells a mouse macrophage line
  • DMEM medium containing 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin. It was. Cells that reached confluence were kept passaged using a scraper.
  • Dehydrogenase present in mitochondria in living cells produces a formazan chromophore in tetrazolium salt (WST). Therefore, by measuring the number of live cells during the extract treatment of wheat germ fermentation was confirmed the toxicity.
  • RAW 264.7 cells at a concentration of 1 ⁇ 10 4 cells / well were incubated in DMEM cultures with 10% FBS, 1% penicillin / streptomycin for 24 hours in 96-well cell culture plates. Thereafter, the cultured RAW 264.7 cells were treated with extracts of the wheat germ fermentation product obtained in Preparation Example 1 for 24 hours at different concentrations (25, 50, 100, 200 and 400 ⁇ g / ml), and then 5 mg / ml MTT solution. DMEM medium containing this was incubated for 48 hours in 37 °C, 5% CO 2 incubator. Thereafter, MTT reagent was removed from the culture solution, and 100 ⁇ l of DMSO was added to each well, followed by dissolving formazan. After absorbance was measured through a 540 nm ELISA detector, cell viability was determined by the following Equation 1.
  • RAW 264.7 macrophages were placed in DMEM medium containing 10% FBS and incubated at 37 ° C. and 5% CO 2 . Thereafter, RAW 264.7 macrophages were dispensed into 96 well plates at 5 ⁇ 10 4 cell counts / well, and 24 hours later, the extracts of wheat germ fermentation were concentrated at 37 ° C., 5% CO at 25, 50, 100, 200 and 400 ⁇ g / ml concentrations, respectively. under the conditions of 2 was treated for 1 hour. Then, in order to induce an inflammatory response, 1 ⁇ g / ml lipopolysaccharide (Lipopolysaccharide, LPS) was treated for 24 hours to induce NO generation.
  • Lipopolysaccharide LPS
  • NO assay Anti-inflammatory efficacy assay
  • a NO detection kit intron based on the Griess response. Specifically, 1% sulfanilamide and 0.1% N- (1-naphthyl) ethylenediamine dihydrochloride (N- (1-naphthyl) ethylenediamine dihydrochloride) by mixing 1: 1 to make a reagent, The supernatant of the 96 well plate treated with the extract of the wheat germ fermentation and the reagent were mixed 1: 1 to react at room temperature. Thereafter, NO production was measured through an ELISA reader at 540 nm. NO production was calculated by using a standard calibration curve using 1M NaNO 2 (Sodium Nitrite).
  • RAW 264.7 cells at a concentration of 1 ⁇ 10 4 cells / well in 96-well cell culture plates were incubated for 24 hours at 37 ° C. and 5% CO 2 in DMEM medium to which 10% FBS, 1% penicillin / streptomycin was added. Then 2,6-DMBQ (Sigma) was replaced with DMEM medium containing concentrations (15 ⁇ g / ml, 30 ⁇ g / ml, 60 ⁇ g / ml and 120 ⁇ g / ml) at 37 ° C., 5% CO 2 . Incubated for 48 hours under conditions. Cell viability was calculated by the above formula 1 by using the EZ-CYTOX reagent in the cultured cells and measuring the absorbance at 450 nm.
  • RAW 264.7 cells were dispensed into 60 mm plates at 2 ⁇ 10 6 cell count / dish density and attached to the plates for 24 hours.
  • 1 ⁇ g / ml LPS and test substance 2,6-DMBQ 15 ⁇ g / ml, 30 ⁇ g / ml, 60 ⁇ g / ml and 120 ⁇ g / ml.
  • the medium was treated and cultured for 24 hours to obtain a culture solution. Thereafter, the amount of NO produced in each culture was measured in the same manner as in Experiment 2.
  • 2,6-DMBQ also has the ability to inhibit NO production in a concentration-dependent manner (FIG. 4).
  • TEWL trans-Epidermal Water Loss
  • a-value skin redness
  • the subject's arm was rinsed off after washing using a reference cleaner, and then divided into two sites at a distance of 5 cm or more from the wrist of the forearm. At each site, the a 0 -value was measured using a TEWL 0 and a chromameter, and the measurements were performed five times.
  • the patch was removed, washed with water and dried, and then TEWL 1 and a 1 -values were measured at each site, and the measurement was performed five times.
  • test site and control site were randomly assigned to two sites, and the test site was attached with a patch containing 15 ⁇ l of 1% wheat germ fermentation extract for 24 hours, and the control site contained an extract of wheat germ fermentation product. Not attached patch.
  • the TEWL 2 and a 2 -values were measured at the test site, and the measurements were performed five times.
  • the patch was removed, washed with water and dried, and then the TEWL 3 and a 3 -values were measured at the test site and control site and the measurements were made five times.
  • Table 1 shows the pre-test homogeneity between the test site and the control site and is statistically significant between the test site and control site measurements both before and after patch (Day-0) and 1 (Say-1) containing 1% SLS solution. One level of difference could not be identified, confirming homogeneity between the test site and the control site prior to sample processing.
  • Table 2 attached the patch containing the 1% SLS solution to the TEWL and a-value increased test site for 24 to 48 hours to extract the extract containing wheat germ fermentation extract, and confirmed the effect on the TEWL and a-value .
  • the increased TEWL and a-value decreased to a statistically significant level (p ⁇ 0.05) compared to the control site after 24 hours and 48 hours, and it was confirmed that the extract of wheat germ fermented product had a skin calming effect.
  • a prescription example of a lotion in cosmetics containing an extract of wheat germ fermentation is as follows.
  • Extract of Wheat Germ Fermentation 1.0 glycerin 5.0 Betaine 3.0 EDTA-2Na 0.02 Xanthan Gum 0.05 DPG-K2 0.02 Allantoin 0.05 Polysorbate 1.0 1,2-hexanediol 1.5 incense 0.03 Distilled water Remaining amount Sum 100
  • a prescription example of a cream in a cosmetic containing wheat germ fermentation is as follows.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)

Abstract

La présente invention concerne une composition topique possédant un excellent effet apaisant sur la peau et, plus particulièrement, une composition cosmétique pour apaiser la peau, une composition pour prévenir ou traiter des maladies inflammatoires de la peau, et une composition quasi-médicamenteuse pour apaiser la peau, comprenant de la 2,6-diméthoxybenzoquinone, ou du germe de blé fermenté ou un extrait de ce dernier.
PCT/KR2017/009499 2016-09-23 2017-08-30 Composition topique pour apaiser la peau, contenant comme principe actif un extrait de germe de blé fermenté WO2018056600A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0122419 2016-09-23
KR20160122419 2016-09-23

Publications (1)

Publication Number Publication Date
WO2018056600A1 true WO2018056600A1 (fr) 2018-03-29

Family

ID=61689860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/009499 WO2018056600A1 (fr) 2016-09-23 2017-08-30 Composition topique pour apaiser la peau, contenant comme principe actif un extrait de germe de blé fermenté

Country Status (3)

Country Link
KR (1) KR101955111B1 (fr)
TW (1) TWI653053B (fr)
WO (1) WO2018056600A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114276958A (zh) * 2021-12-20 2022-04-05 无锡弘焕微生态科技有限公司 具有抗炎功效的三重益生菌发酵复合物的制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102217039B1 (ko) 2019-02-21 2021-02-18 주식회사 유진바이오텍 밀배아 추출물을 유효성분으로 함유하는 백선 개선용 조성물
KR102400146B1 (ko) * 2019-10-28 2022-05-20 주식회사 유진바이오텍 밀배아 추출과 천연 추출물을 유효성분으로 함유하는 여드름 피부 개선용 조성물
CN110613664A (zh) * 2019-10-28 2019-12-27 海南女人春天美容有限公司 一种舒润按摩膏及其制备方法
KR102334971B1 (ko) * 2019-11-28 2021-12-03 주식회사 래디안 밀배아 추출물을 포함하는 두피 및 모발 케어용 화장료 조성물
KR102347742B1 (ko) * 2020-01-15 2022-01-06 주식회사 유진바이오텍 밀배아 성분을 함유하는 피부 개선용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08337536A (ja) * 1995-06-14 1996-12-24 Asahi Breweries Ltd 抗活性酸素作用剤並びにこれを有効成分とする抗活性酸素剤、化粧料、食品及び医薬品
US20050089499A1 (en) * 2002-01-15 2005-04-28 Philippe Moussou Active substances for use in cosmetic and/or pharmaceutical products, obtainable from the fermentation of plant components and/or plant extracts
KR20050059066A (ko) * 2002-08-09 2005-06-17 마테 히드베기 발효된 밀 배 추출물의 항염증제로서의 용도
WO2005077349A1 (fr) * 2004-02-17 2005-08-25 Otsuka Pharmaceutical Co., Ltd. ACCÉLÉRATEUR DE PRODUCTION DE β-DÉFENSINE HUMAINE
US20150182442A1 (en) * 2013-12-31 2015-07-02 Shang Chen Mei Bang (Beijing) Biotechnology Co., Ltd. Traditional chinese medicine composition that has the effect of soothing and cleaning face

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005015450A (ja) * 2003-06-30 2005-01-20 Kanebo Cosmetics Inc 皮膚化粧料
JP2005330273A (ja) * 2004-04-21 2005-12-02 Aol Corporation 生体内ラジカル捕捉組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08337536A (ja) * 1995-06-14 1996-12-24 Asahi Breweries Ltd 抗活性酸素作用剤並びにこれを有効成分とする抗活性酸素剤、化粧料、食品及び医薬品
US20050089499A1 (en) * 2002-01-15 2005-04-28 Philippe Moussou Active substances for use in cosmetic and/or pharmaceutical products, obtainable from the fermentation of plant components and/or plant extracts
KR20050059066A (ko) * 2002-08-09 2005-06-17 마테 히드베기 발효된 밀 배 추출물의 항염증제로서의 용도
WO2005077349A1 (fr) * 2004-02-17 2005-08-25 Otsuka Pharmaceutical Co., Ltd. ACCÉLÉRATEUR DE PRODUCTION DE β-DÉFENSINE HUMAINE
US20150182442A1 (en) * 2013-12-31 2015-07-02 Shang Chen Mei Bang (Beijing) Biotechnology Co., Ltd. Traditional chinese medicine composition that has the effect of soothing and cleaning face

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114276958A (zh) * 2021-12-20 2022-04-05 无锡弘焕微生态科技有限公司 具有抗炎功效的三重益生菌发酵复合物的制备方法和应用

Also Published As

Publication number Publication date
TWI653053B (zh) 2019-03-11
KR20180033438A (ko) 2018-04-03
TW201813624A (zh) 2018-04-16
KR101955111B1 (ko) 2019-03-07

Similar Documents

Publication Publication Date Title
WO2018056600A1 (fr) Composition topique pour apaiser la peau, contenant comme principe actif un extrait de germe de blé fermenté
WO2018174369A1 (fr) Produit de colostrum fermenté par des bactéries lactiques et composition cosmétique l'utilisant
WO2014193014A1 (fr) Bactéries lactiques de taille nanométrique issues du kimchi
KR20140128674A (ko) 피부 주름 개선 및 보습 효능을 갖는 신규의 락토바실러스 플란타룸 ｈｙ７７１４ 및 이를 유효성분으로 함유하는 제품
KR101929658B1 (ko) 밀배아 발효물의 추출물을 유효성분으로 함유하는 피부 미백용 외용제 조성물
WO2018062751A1 (fr) Composition contenant un lysat de lactobacillus plantarum pour les cheveux ou le cuir chevelu
WO2019103329A1 (fr) Composition antioxydante contenant un extrait de ver de farine fermenté à titre de principe actif
WO2020246766A1 (fr) Composition pour prévenir ou atténuer le vieillissement cutané, contenant un extrait de rhodiola sachalinensis fermenté à l'aide de bovista plumbea
WO2019098808A2 (fr) Composition destinée à améliorer les lésions cutanées provoquées par la micropoussière et comprenant une culture ou un extrait de souche d'aureobasidium pullulans
WO2014077621A1 (fr) Composition pour la prévention de la chute des cheveux et l'accélération de la croissance des cheveux
WO2018117725A1 (fr) Composition pour prévenir la chute des cheveux et favoriser la pousse des cheveux, comprenant des produits animaux marins fermentés
WO2015030328A1 (fr) Compositions pour prévenir ou traiter des troubles cutanés allergiques, contenant les agents gpcr19 comme ingrédients actifs
WO2018164369A1 (fr) Composition pour améliorer les rides de la peau, contenant un extrait d'hibiscus syriacus traité par une enzyme en tant que principe actif
WO2017164681A1 (fr) Composition cosmétique destinée à soulager la dermatite atopique, contenant, en tant que principes actifs, une solution de culture de lactobacillus rhamnosus, ou une solution de culture de lactobacillus rhamnosus et de l'acide linoléique conjugué
KR101929657B1 (ko) 밀배아 발효물의 추출물을 유효성분으로 함유하는 피부 주름 개선 외용제 조성물
WO2012173382A2 (fr) Composition à usage externe pour l'épiderme, contenant du tanshinone ii a en tant que principe actif
WO2013115456A1 (fr) Aliment, substance cosmétique, ou composition pharmaceutique contenant un extrait supercritique de gingembre et un extrait de résidu de persil japonais fermenté
KR20110130184A (ko) 항 여드름 효능을 갖는 꾸지뽕나무 추출물과 이를 함유하는 화장료 조성물
KR102053730B1 (ko) 프로바이오틱스 활성을 가지는 신규 엔테로코커스 패칼리스 ami-1001 균주, 및 이의 용도
KR101685121B1 (ko) 발효 밤송이 추출 정제물을 유효성분으로 함유하는 항산화, 또는 항염용 조성물
KR20210056140A (ko) 유리딘 함량이 증가된 적채 발효 추출물 및 이를 포함하는 화장료 조성물 및 이의 제조방법
KR102700826B1 (ko) 알로에 잎 껍질 추출물의 유산균 발효물을 포함하는 기능성 화장료 조성물
KR102517881B1 (ko) 피부 유익균 증진용 화장료 조성물
KR20240008176A (ko) 신규한 락토바실러스 유산균 hk9 복합 발효물의 추출물을 포함하는 기능성 화장품 조성물
WO2018048196A1 (fr) Composition antivieillissement pour la peau contenant de l'acide abiétique déshydrogéné et du composé k

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17853314

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 18.07.2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17853314

Country of ref document: EP

Kind code of ref document: A1